Retour

Arbutus to Participate in Two Upcoming Investor Conferences

Calendar Calendar of Events

WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:

GlobeNewswire Inc. • 07/05/2024 à 13:30:00
Arbutus Biopharma Corporation Common Stock
Address: 701 VETERANS CIRCLE
Postal Code: 18974
City: WARMINSTER
State: PA
Phone Number: 604-419-3200
Website: http://www.arbutusbio.com
Status: Active
Company Info

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

List Date2007-07-26
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001447028
Composite figiBBG000RR8V85
Share Class figiBBG001S6RSK0
Market Cap562,377,879 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees73
Share Class Shares Outstanding188720000
Weighted Shares Outstanding188717409
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
2.975
2.829
2.815
2.861
2.875
Variance
4.53%
0.5%
-1.57%
-0.49%
0.84%
Open
2.846
2.815
2.86
2.875
2.851
Highest
2.998
2.895
2.905
2.895
2.925
Lowest
2.995
2.895
2.903
2.887
2.922
History
PeriodVarhighestlowest
1 week
4.35%
2.925
2.887
1 month
8.38%
2.792
2.745
3 month
-3.38%
3.079
2.565
6 month
60.81%
1.88
1.79
1 year
17.13%
2.62
1.69
3 year
8.58%
2.82
1.69
5 year
26.06%
2.37
0.8214
10 year
-72.4%
11.2
0.8214
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-03 2023-11-07 UNPUB
Assets 191,224,000 176,823,000 158,641,000 UNPUB
Current Assets 152,854,000 158,800,000 141,607,000 UNPUB
Current Liabilities 25,154,000 24,529,000 22,324,000 UNPUB
Equity 143,915,000 134,693,000 119,337,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 143,915,000 134,693,000 119,337,000 UNPUB
Liabilities 47,309,000 42,130,000 39,304,000 UNPUB
Liabilities And Equity 191,224,000 176,823,000 158,641,000 UNPUB
Noncurrent Assets 38,370,000 18,023,000 17,034,000 UNPUB
Noncurrent Liabilities 22,155,000 17,601,000 16,980,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-03 2023-11-07 UNPUB
Exchange Gains/Losses 4,000 -1,000 8,000 UNPUB
Net Cash Flow 9,798,000 -13,377,000 -9,666,000 UNPUB
Net Cash Flow, Continuing 9,794,000 -13,376,000 -9,674,000 UNPUB
Net Cash Flow From Financing Activities 20,417,000 4,742,000 1,681,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 20,417,000 4,742,000 1,681,000 UNPUB
Net Cash Flow From Investing Activities 16,678,000 1,441,000 10,429,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 16,678,000 1,441,000 10,429,000 UNPUB
Net Cash Flow From Operating Activities -27,301,000 -19,559,000 -21,784,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -27,301,000 -19,559,000 -21,784,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-03 2023-11-07 UNPUB
Comprehensive Income/Loss -15,485,000 -16,928,000 -19,520,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -15,485,000 -16,928,000 -19,520,000 UNPUB
Other Comprehensive Income/Loss -15,485,000 -16,928,000 -19,520,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-03 2023-11-07 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses 23,026,000 21,745,000 24,762,000 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 23,026,000 21,745,000 24,762,000 UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -16,339,000 -17,094,000 -20,104,000 UNPUB
Income/Loss From Continuing Operations Before Tax -16,339,000 -17,094,000 -20,104,000 UNPUB
Income Tax Expense/Benefit 0 0 0 UNPUB
Interest Expense, Operating 198,000 171,000 46,000 UNPUB
Net Income/Loss -16,339,000 -17,094,000 -20,104,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -16,339,000 -17,094,000 -20,104,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -16,339,000 -17,094,000 -20,104,000 UNPUB
Operating Expenses 24,100,000 23,036,000 26,216,000 UNPUB
Operating Income/Loss -17,413,000 -18,385,000 -21,558,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 6,687,000 4,651,000 4,658,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-04 2022-11-09 2023-03-02
Assets UNPUB 215,836,000 203,801,000 195,419,000
Current Assets UNPUB 157,791,000 141,136,000 151,139,000
Current Liabilities UNPUB 29,824,000 27,506,000 32,857,000
Equity UNPUB 153,142,000 145,517,000 136,852,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB 153,142,000 145,517,000 136,852,000
Liabilities UNPUB 62,694,000 58,284,000 58,567,000
Liabilities And Equity UNPUB 215,836,000 203,801,000 195,419,000
Noncurrent Assets UNPUB 58,045,000 62,665,000 44,280,000
Noncurrent Liabilities UNPUB 0 30,778,000 25,710,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-04 2022-11-09 2023-03-02
Exchange Gains/Losses UNPUB UNPUB -18,000 -22,000
Net Cash Flow UNPUB UNPUB -23,316,000 -78,506,000
Net Cash Flow, Continuing UNPUB UNPUB -23,298,000 -78,484,000
Net Cash Flow From Financing Activities UNPUB UNPUB 9,132,000 31,814,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 9,132,000 31,814,000
Net Cash Flow From Investing Activities UNPUB UNPUB -13,738,000 -74,942,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -13,738,000 -74,942,000
Net Cash Flow From Operating Activities UNPUB UNPUB -18,692,000 -35,356,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -18,692,000 -35,356,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-04 2022-11-09 2023-03-02
Comprehensive Income/Loss UNPUB -14,883,000 -18,474,000 -71,609,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -14,883,000 -18,474,000 -71,609,000
Other Comprehensive Income/Loss UNPUB -691,000 -907,000 -2,153,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-04 2022-11-09 2023-03-02
Basic Earnings Per Share UNPUB 0 0 0
Benefits Costs and Expenses UNPUB 28,433,000 23,519,000 0
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB 28,433,000 23,519,000 104,475,000
Diluted Earnings Per Share UNPUB 0 0 0
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB -14,192,000 -17,567,000 -69,456,000
Income/Loss From Continuing Operations Before Tax UNPUB -14,192,000 -17,567,000 39,019,000
Income Tax Expense/Benefit UNPUB 0 0 4,444,000
Interest Expense, Operating UNPUB 482,000 429,000 1,726,000
Net Income/Loss UNPUB -14,192,000 -17,567,000 -69,456,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -14,192,000 -17,567,000 -69,456,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -14,192,000 -17,567,000 -69,456,000
Operating Expenses UNPUB 28,350,000 23,763,000 104,475,000
Operating Income/Loss UNPUB -14,109,000 -17,811,000 -65,456,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 0 0 0
Preferred Stock Dividends And Other Adjustments UNPUB 0 0 0
Revenues UNPUB 14,241,000 5,952,000 39,019,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-05 2021-08-05 2021-11-04 2022-03-03
Assets 146,240,000 135,376,000 165,596,000 204,485,000
Current Assets 137,341,000 83,466,000 126,536,000 160,661,000
Current Liabilities 6,693,000 8,841,000 10,113,000 11,221,000
Equity 114,149,000 100,829,000 130,140,000 169,439,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 114,149,000 100,829,000 130,140,000 169,439,000
Liabilities 32,091,000 34,547,000 35,456,000 35,046,000
Liabilities And Equity 146,240,000 135,376,000 165,596,000 204,485,000
Noncurrent Assets 8,899,000 51,910,000 39,060,000 43,824,000
Noncurrent Liabilities 0 0 25,343,000 23,825,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-05 2021-08-05 2021-11-04 2022-03-03
Exchange Gains/Losses -44,000 0 44,000 5,000
Net Cash Flow 27,170,000 -48,467,000 46,929,000 57,031,000
Net Cash Flow, Continuing 27,214,000 -48,467,000 46,885,000 57,026,000
Net Cash Flow From Financing Activities 26,874,000 4,289,000 46,952,000 137,236,000
Net Cash Flow From Financing Activities, Continuing 26,874,000 4,289,000 46,952,000 137,236,000
Net Cash Flow From Investing Activities 18,221,000 -38,747,000 15,969,000 -12,678,000
Net Cash Flow From Investing Activities, Continuing 18,221,000 -38,747,000 15,969,000 -12,678,000
Net Cash Flow From Operating Activities -17,881,000 -14,009,000 -16,036,000 -67,532,000
Net Cash Flow From Operating Activities, Continuing -17,881,000 -14,009,000 -16,036,000 -67,532,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-05 2021-08-05 2021-11-04 2022-03-03
Comprehensive Income/Loss -16,378,000 -19,418,000 -19,189,000 -76,411,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -16,378,000 -19,418,000 -19,189,000 -76,411,000
Other Comprehensive Income/Loss 3,000 -31,000 12,000 -164,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-05 2021-08-05 2021-11-04 2022-03-03
Basic Earnings Per Share 0 0 0 -1
Benefits Costs and Expenses 18,494,000 21,716,000 22,498,000 0
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 18,494,000 21,716,000 22,498,000 84,510,000
Diluted Earnings Per Share 0 0 0 -1
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -16,381,000 -19,387,000 -19,158,000 -76,247,000
Income/Loss From Continuing Operations Before Tax -16,381,000 -19,387,000 -19,158,000 10,988,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating 772,000 763,000 762,000 2,857,000
Net Income/Loss -16,381,000 -19,387,000 -19,158,000 -76,247,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -16,381,000 -19,387,000 -19,158,000 -76,247,000
Net Income/Loss Available To Common Stockholders, Basic -19,593,000 -22,653,000 -24,245,000 -88,386,000
Operating Expenses 17,789,000 20,971,000 21,748,000 84,510,000
Operating Income/Loss -15,676,000 -18,642,000 -18,408,000 -73,522,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 5,087,000 12,139,000
Preferred Stock Dividends And Other Adjustments 3,212,000 3,266,000 5,087,000 12,139,000
Revenues 2,113,000 2,329,000 3,340,000 10,988,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-07 2020-11-05 2021-03-04
Assets 102,614,000 97,625,000 131,104,000 137,080,000
Current Assets 88,333,000 85,536,000 121,242,000 127,704,000
Current Liabilities 4,031,000 6,327,000 7,608,000 9,541,000
Equity 73,256,000 65,511,000 97,345,000 101,966,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 73,256,000 65,511,000 97,345,000 101,966,000
Liabilities 29,358,000 32,114,000 33,759,000 35,114,000
Liabilities And Equity 102,614,000 97,625,000 131,104,000 137,080,000
Noncurrent Assets 14,281,000 12,089,000 9,862,000 9,376,000
Noncurrent Liabilities 0 0 26,151,000 25,573,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-07 2020-11-05 2021-03-04
Exchange Gains/Losses -10,000 -46,000 0 56,000
Net Cash Flow -5,383,000 19,483,000 51,019,000 20,452,000
Net Cash Flow, Continuing -5,373,000 19,529,000 51,019,000 20,396,000
Net Cash Flow From Financing Activities 12,481,000 4,959,000 49,096,000 86,746,000
Net Cash Flow From Financing Activities, Continuing 12,481,000 4,959,000 49,096,000 86,746,000
Net Cash Flow From Investing Activities -2,401,000 23,371,000 14,097,000 -14,909,000
Net Cash Flow From Investing Activities, Continuing -2,401,000 23,371,000 14,097,000 -14,909,000
Net Cash Flow From Operating Activities -15,453,000 -8,801,000 -12,174,000 -51,441,000
Net Cash Flow From Operating Activities, Continuing -15,453,000 -8,801,000 -12,174,000 -51,441,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-07 2020-11-05 2021-03-04
Comprehensive Income/Loss -13,610,000 -13,965,000 -18,783,000 -63,687,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -13,610,000 -13,965,000 -18,783,000 -63,687,000
Other Comprehensive Income/Loss 252,000 -122,000 -72,000 14,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-07 2020-11-05 2021-03-04
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses 15,352,000 15,601,000 20,278,000 70,659,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 15,352,000 15,601,000 20,278,000 70,659,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -13,861,000 -14,087,000 -18,755,000 -63,745,000
Income/Loss From Continuing Operations Before Tax -13,861,000 -14,087,000 -18,755,000 -63,745,000
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating 1,041,000 1,099,000 1,074,000 4,011,000
Net Income/Loss -13,861,000 -14,087,000 -18,755,000 -63,745,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -13,861,000 -14,087,000 -18,755,000 -63,745,000
Net Income/Loss Available To Common Stockholders, Basic -16,839,000 -17,082,000 -21,782,000 -75,868,000
Operating Expenses 14,638,000 14,655,000 16,740,000 64,720,000
Operating Income/Loss -13,147,000 -13,141,000 -15,217,000 -57,806,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 3,027,000 12,123,000
Preferred Stock Dividends And Other Adjustments 2,978,000 2,995,000 3,027,000 12,123,000
Revenues 1,491,000 1,514,000 1,523,000 6,914,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-06 2019-08-05 2019-11-06 2020-03-05
Assets 209,216,000 192,570,000 117,277,000 105,535,000
Current Assets 112,486,000 99,583,000 94,341,000 93,828,000
Current Liabilities 8,823,000 8,799,000 8,817,000 7,828,000
Equity 181,209,000 164,466,000 83,637,000 72,744,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 181,209,000 164,466,000 83,637,000 72,744,000
Liabilities 28,007,000 28,104,000 33,640,000 32,791,000
Liabilities And Equity 209,216,000 192,570,000 117,277,000 105,535,000
Noncurrent Assets 96,730,000 92,987,000 22,936,000 11,707,000
Noncurrent Liabilities 0 0 24,823,000 24,963,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-06 2019-08-05 2019-11-06 2020-03-05
Exchange Gains/Losses 38,000 57,000 -24,000 68,000
Net Cash Flow 47,027,000 -5,097,000 11,210,000 -5,143,000
Net Cash Flow, Continuing 46,989,000 -5,154,000 11,234,000 -5,211,000
Net Cash Flow From Financing Activities 2,536,000 2,479,000 18,549,000 37,457,000
Net Cash Flow From Financing Activities, Continuing 2,536,000 2,479,000 18,549,000 37,457,000
Net Cash Flow From Investing Activities 61,033,000 9,972,000 16,155,000 28,338,000
Net Cash Flow From Investing Activities, Continuing 61,033,000 9,972,000 16,155,000 28,338,000
Net Cash Flow From Operating Activities -16,580,000 -17,605,000 -23,470,000 -71,006,000
Net Cash Flow From Operating Activities, Continuing -16,580,000 -17,605,000 -23,470,000 -71,006,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-06 2019-08-05 2019-11-06 2020-03-05
Comprehensive Income/Loss -23,251,000 -23,315,000 -82,503,000 -153,782,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -23,273,000 -23,367,000 -82,476,000 -153,782,000
Other Comprehensive Income/Loss -22,000 -52,000 27,000 -59,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-06 2019-08-05 2019-11-06 2020-03-05
Basic Earnings Per Share 0 0 -2 -3
Benefits Costs and Expenses 0 0 0 172,390,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 19,750,000 21,168,000 94,462,000 172,390,000
Diluted Earnings Per Share 0 0 UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -23,251,000 -23,315,000 -82,503,000 -153,723,000
Income/Loss From Continuing Operations Before Tax 679,000 -23,315,000 -95,159,000 -166,379,000
Income Tax Expense/Benefit UNPUB UNPUB -12,656,000 -12,656,000
Interest Expense, Operating 12,000 2,000 1,100,000 2,108,000
Net Income/Loss -23,251,000 -23,315,000 -82,503,000 -153,723,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -23,251,000 -23,315,000 -82,503,000 -153,723,000
Net Income/Loss Available To Common Stockholders, Basic -25,966,000 -26,077,000 -85,295,000 -164,872,000
Operating Expenses 19,750,000 21,168,000 94,462,000 150,085,000
Operating Income/Loss -19,071,000 -20,515,000 -91,401,000 -144,074,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 2,715,000 2,762,000 2,792,000 11,149,000
Preferred Stock Dividends And Other Adjustments 2,715,000 2,762,000 2,792,000 11,149,000
Revenues 679,000 653,000 3,061,000 6,011,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-04 2018-08-03 2018-11-07 2019-03-07
Assets 270,026,000 277,014,000 245,418,000 227,905,000
Current Assets 175,186,000 157,769,000 144,025,000 129,229,000
Current Liabilities 10,396,000 11,541,000 12,668,000 11,239,000
Equity 232,418,000 238,072,000 215,272,000 200,234,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 232,418,000 238,072,000 215,272,000 200,234,000
Liabilities 37,608,000 38,942,000 30,146,000 27,671,000
Liabilities And Equity 270,026,000 277,014,000 245,418,000 227,905,000
Noncurrent Assets 94,840,000 119,245,000 101,393,000 98,676,000
Noncurrent Liabilities 0 0 17,478,000 16,432,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-04 2018-08-03 2018-11-07 2019-03-07
Exchange Gains/Losses -565,000 -361,000 131,000 -1,003,000
Net Cash Flow -41,831,000 -2,268,000 11,740,000 -17,350,000
Net Cash Flow, Continuing -41,266,000 -1,907,000 11,609,000 -16,347,000
Net Cash Flow From Financing Activities 54,367,000 735,000 435,000 55,646,000
Net Cash Flow From Financing Activities, Continuing 54,367,000 735,000 435,000 55,646,000
Net Cash Flow From Investing Activities -75,666,000 14,980,000 24,378,000 -4,127,000
Net Cash Flow From Investing Activities, Continuing -75,666,000 14,980,000 24,378,000 -4,127,000
Net Cash Flow From Operating Activities -19,967,000 -17,622,000 -13,204,000 -67,866,000
Net Cash Flow From Operating Activities, Continuing -19,967,000 -17,622,000 -13,204,000 -67,866,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-04 2018-08-03 2018-11-07 2019-03-07
Comprehensive Income/Loss -17,429,000 3,091,000 -24,473,000 -57,045,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -17,429,000 3,091,000 -24,485,000 -57,045,000
Other Comprehensive Income/Loss 0 0 -12,000 15,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-04 2018-08-03 2018-11-07 2019-03-07
Basic Earnings Per Share 0 0 0 -1
Benefits Costs and Expenses 0 0 0 67,287,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 19,841,000 23,290,000 34,013,000 67,287,000
Diluted Earnings Per Share 0 0 0 -1
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -17,429,000 3,091,000 -24,473,000 -57,060,000
Income/Loss From Continuing Operations Before Tax 1,436,000 1,244,000 -28,755,000 -61,342,000
Income Tax Expense/Benefit UNPUB UNPUB -4,282,000 -4,282,000
Interest Expense, Operating 104,000 0 0 226,000
Net Income/Loss -17,429,000 3,091,000 -24,473,000 -57,060,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -17,429,000 3,091,000 -24,473,000 -57,060,000
Net Income/Loss Available To Common Stockholders, Basic -19,765,000 550,000 -27,040,000 -67,151,000
Operating Expenses 19,841,000 23,290,000 34,013,000 95,725,000
Operating Income/Loss -18,405,000 -22,046,000 -32,426,000 -89,780,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 2,336,000 2,541,000 2,567,000 10,091,000
Preferred Stock Dividends And Other Adjustments 2,336,000 2,541,000 2,567,000 10,091,000
Revenues 1,436,000 1,244,000 1,587,000 5,945,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2017-05-04 2017-08-03 2017-11-02 2018-03-16
Assets 268,140,000 255,075,000 239,845,000 237,161,000
Current Assets 120,268,000 105,922,000 90,813,000 129,366,000
Current Liabilities 10,871,000 11,881,000 8,235,000 14,627,000
Equity 189,098,000 175,786,000 167,391,000 182,473,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 189,098,000 175,786,000 167,391,000 182,473,000
Liabilities 79,042,000 79,289,000 72,454,000 54,688,000
Liabilities And Equity 268,140,000 255,075,000 239,845,000 237,161,000
Noncurrent Assets 147,872,000 149,153,000 149,032,000 107,795,000
Noncurrent Liabilities 68,171,000 67,408,000 64,219,000 40,061,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2017-05-04 2017-08-03 2017-11-02 2018-03-16
Exchange Gains/Losses 424,000 825,000 1,327,000 2,372,000
Net Cash Flow 6,438,000 -5,639,000 -8,987,000 30,879,000
Net Cash Flow, Continuing 6,014,000 -6,464,000 -10,314,000 28,507,000
Net Cash Flow From Financing Activities 354,000 4,000 61,000 49,322,000
Net Cash Flow From Financing Activities, Continuing 354,000 4,000 61,000 49,322,000
Net Cash Flow From Investing Activities 23,195,000 -1,390,000 5,305,000 27,825,000
Net Cash Flow From Investing Activities, Continuing 23,195,000 -1,390,000 5,305,000 27,825,000
Net Cash Flow From Operating Activities -17,535,000 -5,078,000 -15,680,000 -48,640,000
Net Cash Flow From Operating Activities, Continuing -17,535,000 -5,078,000 -15,680,000 -48,640,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2017-05-04 2017-08-03 2017-11-02 2018-03-16
Comprehensive Income/Loss -18,627,000 -18,255,000 -11,600,000 -84,413,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -18,627,000 -18,255,000 -11,600,000 -84,413,000
Other Comprehensive Income/Loss 0 0 0 -84,413,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2017-05-04 2017-08-03 2017-11-02 2018-03-16
Basic Earnings Per Share UNPUB UNPUB UNPUB -2
Benefits Costs and Expenses 0 0 0 119,433,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 18,534,000 20,524,000 19,789,000 119,433,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -18,627,000 -18,255,000 -11,600,000 -84,413,000
Income/Loss From Continuing Operations Before Tax 235,000 -18,255,000 -11,600,000 -108,733,000
Income Tax Expense/Benefit 0 0 0 -24,320,000
Interest Expense, Operating 42,000 68,000 76,000 261,000
Net Income/Loss -18,627,000 -18,255,000 -11,600,000 -84,413,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -18,627,000 -18,255,000 -11,600,000 -84,413,000
Net Income/Loss Available To Common Stockholders, Basic -18,627,000 -18,255,000 -11,600,000 -85,324,000
Operating Expenses 18,534,000 20,524,000 19,789,000 121,630,000
Operating Income/Loss -18,299,000 -19,485,000 -12,897,000 -110,930,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 911,000
Preferred Stock Dividends And Other Adjustments 0 0 0 911,000
Revenues 235,000 1,039,000 6,892,000 10,700,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2016-05-04 2016-08-04 2016-11-03 2017-03-22
Assets 703,254,000 530,861,000 514,730,000 275,919,000
Current Assets 174,757,000 168,085,000 151,812,000 132,564,000
Current Liabilities 11,112,000 10,084,000 8,392,000 10,585,000
Equity 538,077,000 431,324,000 416,625,000 203,005,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 538,077,000 431,324,000 416,625,000 203,005,000
Liabilities 165,177,000 99,537,000 98,105,000 72,914,000
Liabilities And Equity 703,254,000 530,861,000 514,730,000 275,919,000
Noncurrent Assets 528,497,000 362,776,000 362,918,000 143,355,000
Noncurrent Liabilities 154,065,000 89,453,000 89,713,000 62,329,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2016-05-04 2016-08-04 2016-11-03 2017-03-22
Exchange Gains/Losses 3,006,000 -51,000 -824,000 1,004,000
Net Cash Flow -22,007,000 -101,802,000 -16,340,000 -143,366,000
Net Cash Flow, Continuing -25,013,000 -101,751,000 -15,516,000 -144,370,000
Net Cash Flow From Financing Activities 115,000 446,000 76,000 12,638,000
Net Cash Flow From Financing Activities, Continuing 115,000 446,000 76,000 12,638,000
Net Cash Flow From Investing Activities -13,582,000 -85,393,000 -880,000 -99,123,000
Net Cash Flow From Investing Activities, Continuing -13,582,000 -85,393,000 -880,000 -99,123,000
Net Cash Flow From Operating Activities -11,546,000 -16,804,000 -14,712,000 -57,885,000
Net Cash Flow From Operating Activities, Continuing -11,546,000 -16,804,000 -14,712,000 -57,885,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2016-05-04 2016-08-04 2016-11-03 2017-03-22
Comprehensive Income/Loss -15,874,000 -130,000,000 -19,595,000 -384,164,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -15,874,000 -130,000,000 -19,595,000 -384,164,000
Other Comprehensive Income/Loss 0 0 0 -384,164,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2016-05-04 2016-08-04 2016-11-03 2017-03-22
Basic Earnings Per Share UNPUB UNPUB UNPUB -7
Benefits Costs and Expenses 0 0 0 490,657,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 20,580,000 195,557,000 19,749,000 490,657,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB -7
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -15,874,000 -130,000,000 -19,595,000 -384,164,000
Income/Loss From Continuing Operations Before Tax 603,000 -194,864,000 -19,595,000 -489,166,000
Income Tax Expense/Benefit 0 -64,864,000 0 -105,002,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -15,874,000 -130,000,000 -19,595,000 -384,164,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -15,874,000 -130,000,000 -19,595,000 -384,164,000
Net Income/Loss Available To Common Stockholders, Basic -15,874,000 -130,000,000 -19,595,000 -384,164,000
Operating Expenses 20,580,000 195,557,000 19,749,000 493,130,000
Operating Income/Loss -19,977,000 -195,248,000 -18,975,000 -491,639,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 603,000 309,000 774,000 1,491,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2015-11-05 2016-03-09
Assets UNPUB UNPUB 722,631,000 712,291,000
Current Assets UNPUB UNPUB 200,027,000 183,882,000
Current Liabilities UNPUB UNPUB 13,831,000 10,578,000
Equity UNPUB UNPUB 553,807,000 547,679,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Equity Attributable To Parent UNPUB UNPUB 553,807,000 547,679,000
Liabilities UNPUB UNPUB 168,824,000 164,612,000
Liabilities And Equity UNPUB UNPUB 722,631,000 712,291,000
Noncurrent Assets UNPUB UNPUB 522,604,000 528,409,000
Noncurrent Liabilities UNPUB UNPUB 154,993,000 154,034,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2015-11-05 2016-03-09
Exchange Gains/Losses UNPUB UNPUB -5,972,000 -2,175,000
Net Cash Flow UNPUB UNPUB -26,116,000 94,592,000
Net Cash Flow, Continuing UNPUB UNPUB -20,144,000 96,767,000
Net Cash Flow From Financing Activities UNPUB UNPUB 116,000 143,870,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 116,000 143,870,000
Net Cash Flow From Investing Activities UNPUB UNPUB -17,733,000 7,682,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -17,733,000 7,682,000
Net Cash Flow From Operating Activities UNPUB UNPUB -2,527,000 -54,785,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -2,527,000 -54,785,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2015-11-05 2016-03-09
Comprehensive Income/Loss UNPUB UNPUB -28,982,000 -88,590,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -39,083,000 -88,590,000
Other Comprehensive Income/Loss UNPUB UNPUB 0 -88,590,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2015-11-05 2016-03-09
Basic Earnings Per Share UNPUB UNPUB UNPUB -1
Benefits Costs and Expenses UNPUB UNPUB 0 102,179,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB 62,203,000 102,179,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB -1
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -28,982,000 -61,121,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -44,178,000 -77,306,000
Income Tax Expense/Benefit UNPUB UNPUB -15,196,000 -16,185,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB -28,982,000 -61,121,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Net Income/Loss Attributable To Parent UNPUB UNPUB -28,982,000 -61,121,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -28,982,000 -61,121,000
Operating Expenses UNPUB UNPUB 62,203,000 127,195,000
Operating Income/Loss UNPUB UNPUB -58,138,000 -102,322,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 0 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 0 0
Revenues UNPUB UNPUB 4,065,000 24,873,000
Calendar
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:ABUS240517P00004500 OPASPS Put American 100 4.5 BATO 2024-05-17
O:ABUS240517P00003500 OPASPS Put American 100 3.5 BATO 2024-05-17
O:ABUS240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:ABUS240517P00001500 OPASPS Put American 100 1.5 BATO 2024-05-17
O:ABUS240517P00000500 OPASPS Put American 100 0.5 BATO 2024-05-17
O:ABUS240517C00004500 OCASPS Call American 100 4.5 BATO 2024-05-17
O:ABUS240517C00003500 OCASPS Call American 100 3.5 BATO 2024-05-17
O:ABUS240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:ABUS240517C00001500 OCASPS Call American 100 1.5 BATO 2024-05-17
O:ABUS240517C00000500 OCASPS Call American 100 0.5 BATO 2024-05-17
O:ABUS240517P00006000 OPASPS Put American 100 6 BATO 2024-05-17
O:ABUS240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:ABUS240517P00004000 OPASPS Put American 100 4 BATO 2024-05-17
O:ABUS240517P00003000 OPASPS Put American 100 3 BATO 2024-05-17
O:ABUS240517P00002000 OPASPS Put American 100 2 BATO 2024-05-17
O:ABUS240517P00001000 OPASPS Put American 100 1 BATO 2024-05-17
O:ABUS240517C00006000 OCASPS Call American 100 6 BATO 2024-05-17
O:ABUS240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:ABUS240517C00004000 OCASPS Call American 100 4 BATO 2024-05-17
O:ABUS240517C00003000 OCASPS Call American 100 3 BATO 2024-05-17
O:ABUS240517C00002000 OCASPS Call American 100 2 BATO 2024-05-17
O:ABUS240517C00001000 OCASPS Call American 100 1 BATO 2024-05-17
O:ABUS240419P00006000 OPASPS Put American 100 6 BATO 2024-04-19
O:ABUS240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:ABUS240419P00004000 OPASPS Put American 100 4 BATO 2024-04-19
O:ABUS240419P00003000 OPASPS Put American 100 3 BATO 2024-04-19
O:ABUS240419P00002000 OPASPS Put American 100 2 BATO 2024-04-19
O:ABUS240419P00001000 OPASPS Put American 100 1 BATO 2024-04-19
O:ABUS240419C00006000 OCASPS Call American 100 6 BATO 2024-04-19
O:ABUS240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:ABUS240419C00004000 OCASPS Call American 100 4 BATO 2024-04-19
O:ABUS240419C00003000 OCASPS Call American 100 3 BATO 2024-04-19
O:ABUS240419C00002000 OCASPS Call American 100 2 BATO 2024-04-19
O:ABUS240419C00001000 OCASPS Call American 100 1 BATO 2024-04-19
O:ABUS240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:ABUS240315P00004000 OPASPS Put American 100 4 BATO 2024-03-15
O:ABUS240315P00003000 OPASPS Put American 100 3 BATO 2024-03-15
O:ABUS240315P00002000 OPASPS Put American 100 2 BATO 2024-03-15
O:ABUS240315P00001000 OPASPS Put American 100 1 BATO 2024-03-15
O:ABUS240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:ABUS240315C00004000 OCASPS Call American 100 4 BATO 2024-03-15
O:ABUS240315C00003000 OCASPS Call American 100 3 BATO 2024-03-15
O:ABUS240315C00002000 OCASPS Call American 100 2 BATO 2024-03-15
O:ABUS240315C00001000 OCASPS Call American 100 1 BATO 2024-03-15
O:ABUS240315P00006000 OPASPS Put American 100 6 BATO 2024-03-15
O:ABUS240315C00006000 OCASPS Call American 100 6 BATO 2024-03-15
O:ABUS240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:ABUS240216P00004000 OPASPS Put American 100 4 BATO 2024-02-16
O:ABUS240216P00003000 OPASPS Put American 100 3 BATO 2024-02-16
O:ABUS240216P00002000 OPASPS Put American 100 2 BATO 2024-02-16
O:ABUS240216P00001000 OPASPS Put American 100 1 BATO 2024-02-16
O:ABUS240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:ABUS240216C00004000 OCASPS Call American 100 4 BATO 2024-02-16
O:ABUS240216C00003000 OCASPS Call American 100 3 BATO 2024-02-16
O:ABUS240216C00002000 OCASPS Call American 100 2 BATO 2024-02-16
O:ABUS240216C00001000 OCASPS Call American 100 1 BATO 2024-02-16
O:ABUS240216P00006000 OPASPS Put American 100 6 BATO 2024-02-16
O:ABUS240216C00006000 OCASPS Call American 100 6 BATO 2024-02-16
O:ABUS240119C00003000 OCASPS Call American 100 3 BATO 2024-01-19
O:ABUS240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:ABUS240119C00002000 OCASPS Call American 100 2 BATO 2024-01-19
O:ABUS240119C00001500 OCASPS Call American 100 1.5 BATO 2024-01-19
O:ABUS240119C00001000 OCASPS Call American 100 1 BATO 2024-01-19
O:ABUS240119C00000500 OCASPS Call American 100 0.5 BATO 2024-01-19
O:ABUS240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:ABUS240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:ABUS240119P00005500 OPASPS Put American 100 5.5 BATO 2024-01-19
O:ABUS240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:ABUS240119P00004500 OPASPS Put American 100 4.5 BATO 2024-01-19
O:ABUS240119P00004000 OPASPS Put American 100 4 BATO 2024-01-19
O:ABUS240119P00003500 OPASPS Put American 100 3.5 BATO 2024-01-19
O:ABUS240119P00003000 OPASPS Put American 100 3 BATO 2024-01-19
O:ABUS240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:ABUS240119P00002000 OPASPS Put American 100 2 BATO 2024-01-19
O:ABUS240119P00001500 OPASPS Put American 100 1.5 BATO 2024-01-19
O:ABUS240119P00001000 OPASPS Put American 100 1 BATO 2024-01-19
O:ABUS240119P00000500 OPASPS Put American 100 0.5 BATO 2024-01-19
O:ABUS240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:ABUS240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:ABUS240119C00005500 OCASPS Call American 100 5.5 BATO 2024-01-19
O:ABUS240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:ABUS240119C00004500 OCASPS Call American 100 4.5 BATO 2024-01-19
O:ABUS240119C00004000 OCASPS Call American 100 4 BATO 2024-01-19
O:ABUS240119C00003500 OCASPS Call American 100 3.5 BATO 2024-01-19
O:ABUS231215P00006000 OPASPS Put American 100 6 BATO 2023-12-15
O:ABUS231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:ABUS231215P00004000 OPASPS Put American 100 4 BATO 2023-12-15
O:ABUS231215P00003000 OPASPS Put American 100 3 BATO 2023-12-15
O:ABUS231215P00002000 OPASPS Put American 100 2 BATO 2023-12-15
O:ABUS231215P00001000 OPASPS Put American 100 1 BATO 2023-12-15
O:ABUS231215C00006000 OCASPS Call American 100 6 BATO 2023-12-15
O:ABUS231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:ABUS231215C00004000 OCASPS Call American 100 4 BATO 2023-12-15
O:ABUS231215C00003000 OCASPS Call American 100 3 BATO 2023-12-15
O:ABUS231215C00002000 OCASPS Call American 100 2 BATO 2023-12-15
O:ABUS231215C00001000 OCASPS Call American 100 1 BATO 2023-12-15
O:ABUS231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:ABUS231117P00004000 OPASPS Put American 100 4 BATO 2023-11-17
O:ABUS231117P00003000 OPASPS Put American 100 3 BATO 2023-11-17
O:ABUS231117P00002000 OPASPS Put American 100 2 BATO 2023-11-17
O:ABUS231117P00001000 OPASPS Put American 100 1 BATO 2023-11-17
O:ABUS231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:ABUS231117C00004000 OCASPS Call American 100 4 BATO 2023-11-17
O:ABUS231117C00003000 OCASPS Call American 100 3 BATO 2023-11-17
O:ABUS231117C00002000 OCASPS Call American 100 2 BATO 2023-11-17
O:ABUS231117C00001000 OCASPS Call American 100 1 BATO 2023-11-17
O:ABUS231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:ABUS231020P00004000 OPASPS Put American 100 4 BATO 2023-10-20
O:ABUS231020P00003000 OPASPS Put American 100 3 BATO 2023-10-20
O:ABUS231020P00002000 OPASPS Put American 100 2 BATO 2023-10-20
O:ABUS231020P00001000 OPASPS Put American 100 1 BATO 2023-10-20
O:ABUS231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:ABUS231020C00004000 OCASPS Call American 100 4 BATO 2023-10-20
O:ABUS231020C00003000 OCASPS Call American 100 3 BATO 2023-10-20
O:ABUS231020C00002000 OCASPS Call American 100 2 BATO 2023-10-20
O:ABUS231020C00001000 OCASPS Call American 100 1 BATO 2023-10-20
O:ABUS230915P00006000 OPASPS Put American 100 6 BATO 2023-09-15
O:ABUS230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:ABUS230915P00004000 OPASPS Put American 100 4 BATO 2023-09-15
O:ABUS230915P00003000 OPASPS Put American 100 3 BATO 2023-09-15
O:ABUS230915P00002000 OPASPS Put American 100 2 BATO 2023-09-15
O:ABUS230915P00001000 OPASPS Put American 100 1 BATO 2023-09-15
O:ABUS230915C00006000 OCASPS Call American 100 6 BATO 2023-09-15
O:ABUS230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:ABUS230915C00004000 OCASPS Call American 100 4 BATO 2023-09-15
O:ABUS230915C00003000 OCASPS Call American 100 3 BATO 2023-09-15
O:ABUS230915C00002000 OCASPS Call American 100 2 BATO 2023-09-15
O:ABUS230915C00001000 OCASPS Call American 100 1 BATO 2023-09-15
O:ABUS230818C00002000 OCASPS Call American 100 2 BATO 2023-08-18
O:ABUS230818C00001000 OCASPS Call American 100 1 BATO 2023-08-18
O:ABUS230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:ABUS230818P00004000 OPASPS Put American 100 4 BATO 2023-08-18
O:ABUS230818P00003000 OPASPS Put American 100 3 BATO 2023-08-18
O:ABUS230818P00002000 OPASPS Put American 100 2 BATO 2023-08-18
O:ABUS230818P00001000 OPASPS Put American 100 1 BATO 2023-08-18
O:ABUS230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:ABUS230818C00004000 OCASPS Call American 100 4 BATO 2023-08-18
O:ABUS230818C00003000 OCASPS Call American 100 3 BATO 2023-08-18
News Stream
Calendar Calendar of Events
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:
GlobeNewswire Inc. • 1w ago
Management Directors and Officers
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that after a distinguished 38-year career, the Company’s co-founder and Chief Scientific Officer, Dr. Michael Sofia, will retire effective December 31, 2024. Dr. Sofia is a globally recognized, Lasker award-winning antiviral drug discovery and development scientist.
GlobeNewswire Inc. • 2w ago
Calendar Calendar of Events
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024. The schedule for the press release and conference call/webcast are as follows:
GlobeNewswire Inc. • 1mo ago
News Law & Legal Issues
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today issued the following statement regarding the claim construction ruling of the U.S. District Court for the District of Delaware in the lawsuit brought by Arbutus and its licensee Genevant Sciences (Plaintiffs) against Moderna, Inc. and a Moderna affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19.
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:
GlobeNewswire Inc. • 2mo ago
News News
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 54.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research • 2mo ago
Calendar Calendar of Events
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024. The schedule for the press release and conference call/webcast are as follows:
GlobeNewswire Inc. • 3mo ago
News Clinical Study
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024
GlobeNewswire Inc. • 4mo ago
News Clinical Study
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline
GlobeNewswire Inc. • 6mo ago
Calendar Calendar of Events
Arbutus to Present at Jefferies London Healthcare Conference
WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference:
GlobeNewswire Inc. • 6mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT